NCT02039063View on ClinicalTrials.gov

A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 5, 2014

Primary Completion Date

January 6, 2017

Study Completion Date

November 27, 2017

Conditions

Crohn's Disease

Interventions

DRUG

E6011 2 mg/kg

DRUG

E6011 5 mg/kg

DRUG

E6011 10 mg/kg

DRUG

E6011 15 mg/kg

Trial Locations (17)

Unknown

Nagoya

Chikushino-shi

Kurume

Asahikawa

Nishinomiya

Kanazawa

Morioka

Sagamihara

Tsu

Urazoe

Takatsuki

Minato-ku

Shinjuku-ku

Chiba

Fukuoka

Kyoto

Osaka

All Listed Sponsors

lead

EA Pharma Co., Ltd.

INDUSTRY

NCT02039063 - A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease | Biotech Hunter | Biotech Hunter